The objective of this study was to investigate the impact of COVID-19 on children receiving immunosuppressive therapies for neuroimmunologic disorders.

One year on from the onset of the COVID-19 pandemic, the authors aimed to summarise the frequency of neurological manifestations reported in COVID-19 patients and investigate the association of these manifestations with disease severity and mortality.

In this article the authors have developed a postmortem bedside surgical procedure to harvest endoscopically samples of respiratory and olfactory mucosae and whole olfactory bulbs.

The objective of this randomised, double blind, placebo controlled trial was to determine if inhaled and intranasal ciclesonide are superior to placebo at decreasing respiratory symptoms in adult outpatients with COVID-19.

The objective of this systematic review and meta-analysis was to review the evidence on the effectiveness of public health measures in reducing the incidence of COVID-19, SARS-CoV-2 transmission, and COVID-19 mortality.

In this article the authors used the healthcare databases of the US to estimate that burden of PASC was 73.43 (72.10, 74.72) per 1000 persons at 6 months.

In this article the authors report an analysis of postmortem COVID-19 cases that provides proof of viremia and presence of replication-competent SARS-CoV-2 in extrapulmonary organs of immunocompromised patients, including heart, kidney, liver, and spleen.

The objective of this study was to investigate the association of SSRIs with outcomes in patients with COVID-19 by analyzing electronic health records (EHRs).

The objective of this study was to assess risk of incident or repeat psychiatric illness, fatigue, or sleep problems following SARS-CoV-2 infection and to analyze changes according to demographic subgroups.

In this study the authors aimed to investigate transmission and viral load kinetics in vaccinated and unvaccinated individuals with mild delta variant infection in the community.

In this article the authors aimed to use the data repositories of Israel's largest health-care organisation to evaluate the effectiveness of a third dose of the BNT162b2 mRNA vaccine for preventing severe COVID-19 outcomes.

In this trial, done at 43 centres in France, the authors randomly assigned patients receiving invasive mechanical ventilation for up to 72 h with COVID-19 and associated moderate-to-severe ARDS to receive either IVIG or placebo.

Adults in receipt of a single dose of ChAdOx1 or BNT162b2 were enrolled at 12 UK sites and randomly assigned to receive concomitant administration of either an age-appropriate influenza vaccine or placebo alongside their second dose of COVID-19 vaccine.

In this study the authors did a multicentric, open-label, Bayesian randomised, adaptive, phase 2/3 clinical trial, nested within the CORIMUNO-19 cohort, to test a superiority hypothesis.

In this article the authors aimed to report the results of a substudy within a phase 3 UK trial, by evaluating the safety, immunogenicity, and efficacy of NVX-CoV2373 when co-administered with licensed seasonal influenza vaccines.